News stories about Acorda Therapeutics (NASDAQ:ACOR) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Acorda Therapeutics earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.3404655879938 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the media stories that may have impacted Accern Sentiment’s rankings:

Shares of Acorda Therapeutics (NASDAQ ACOR) opened at $21.05 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.40 and a current ratio of 2.77. Acorda Therapeutics has a 12 month low of $13.60 and a 12 month high of $33.00.

Acorda Therapeutics (NASDAQ:ACOR) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.43 EPS for the quarter, missing the Zacks’ consensus estimate of $0.69 by ($0.26). Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The firm had revenue of $141.07 million during the quarter, compared to the consensus estimate of $150.64 million. During the same period in the prior year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was up 4.0% compared to the same quarter last year. research analysts forecast that Acorda Therapeutics will post -0.18 EPS for the current year.

Several equities analysts have issued reports on the stock. Goldman Sachs Group restated a “sell” rating and issued a $20.00 price target on shares of Acorda Therapeutics in a research report on Friday, October 6th. Raymond James Financial cut shares of Acorda Therapeutics from a “market perform” rating to an “underperform” rating and upped their price target for the company from $7.00 to $13.00 in a research report on Thursday, November 16th. Stifel Nicolaus restated a “buy” rating and issued a $26.00 price target (down from $30.00) on shares of Acorda Therapeutics in a research report on Thursday, August 31st. J P Morgan Chase & Co set a $24.00 price target on shares of Acorda Therapeutics and gave the company a “hold” rating in a research report on Tuesday, October 31st. Finally, BidaskClub upgraded shares of Acorda Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $21.47.

In other news, insider Burkhard Blank sold 11,050 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $20.53, for a total value of $226,856.50. Following the sale, the insider now directly owns 33,150 shares of the company’s stock, valued at approximately $680,569.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 7.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/12/18/acorda-therapeutics-acor-receiving-somewhat-positive-media-coverage-report-shows.html.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.